248 related articles for article (PubMed ID: 19888784)
1. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study.
Stauffer J; Setnik B; Sokolowska M; Romach M; Johnson F; Sellers E
Clin Drug Investig; 2009; 29(12):777-90. PubMed ID: 19888784
[TBL] [Abstract][Full Text] [Related]
2. Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recreational opioid users.
Setnik B; Sommerville K; Goli V; Han L; Webster L
Pain Med; 2013 Aug; 14(8):1173-86. PubMed ID: 23745947
[TBL] [Abstract][Full Text] [Related]
3. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users.
Webster LR; Johnson FK; Stauffer J; Setnik B; Ciric S
Drugs R D; 2011 Sep; 11(3):259-75. PubMed ID: 21902287
[TBL] [Abstract][Full Text] [Related]
4. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers.
Johnson FK; Stark JG; Bieberdorf FA; Stauffer J
Clin Ther; 2010 Jun; 32(6):1149-64. PubMed ID: 20637968
[TBL] [Abstract][Full Text] [Related]
5. Morphine sulfate and naltrexone hydrochloride extended-release capsules: naltrexone release, pharmacodynamics, and tolerability.
Johnson F; Setnik B
Pain Physician; 2011; 14(4):391-406. PubMed ID: 21785483
[TBL] [Abstract][Full Text] [Related]
6. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety.
Katz N; Sun S; Johnson F; Stauffer J
J Pain; 2010 Apr; 11(4):303-11. PubMed ID: 19944650
[TBL] [Abstract][Full Text] [Related]
7. Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users.
Setnik B; Bass A; Bramson C; Levy-Cooperman N; Malhotra B; Matschke K; Geoffroy P; Sommerville KW; Wolfram G
Pain Med; 2017 Jun; 18(6):1077-1088. PubMed ID: 27550954
[TBL] [Abstract][Full Text] [Related]
8. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients.
Setnik B; Roland CL; Goli V; Sommerville K; Webster L
J Opioid Manag; 2013; 9(2):139-50. PubMed ID: 23709323
[TBL] [Abstract][Full Text] [Related]
9. Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users.
Setnik B; Bramson C; Bass A; Levy-Cooperman N; Malhotra B; Matschke K; Sommerville KW; Wolfram G; Geoffroy P
J Clin Pharmacol; 2015 Dec; 55(12):1351-61. PubMed ID: 26011742
[TBL] [Abstract][Full Text] [Related]
10. Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users.
Setnik B; Goli V; Levy-Cooperman N; Mills C; Shram M; Smith I
Pain Res Manag; 2013; 18(4):e55-62. PubMed ID: 23936895
[TBL] [Abstract][Full Text] [Related]
11. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain.
Webster LR; Brewer R; Wang C; Sekora D; Johnson FK; Morris D; Stauffer J
J Pain Symptom Manage; 2010 Nov; 40(5):734-46. PubMed ID: 21075272
[TBL] [Abstract][Full Text] [Related]
13. Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users.
Backonja M; Webster LR; Setnik B; Bass A; Sommerville KW; Matschke K; Malhotra BK; Wolfram G
Am J Drug Alcohol Abuse; 2016 Sep; 42(5):539-549. PubMed ID: 27211522
[TBL] [Abstract][Full Text] [Related]
14. Morphine sulfate and naltrexone hydrochloride extended release capsules for the management of chronic, moderate-to-severe pain, while reducing morphine-induced subjective effects upon tampering by crushing.
Smith HS
Expert Opin Pharmacother; 2011 May; 12(7):1111-25. PubMed ID: 21470065
[TBL] [Abstract][Full Text] [Related]
15. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.
Setnik B; Schoedel K; Bartlett C; Dick C; Hakim N; Geoffroy P
J Opioid Manag; 2017; 13(6):449-464. PubMed ID: 29308591
[TBL] [Abstract][Full Text] [Related]
16. The relative bioavailability of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA®) and an extended release morphine sulfate capsule formulation (KADIAN®) in healthy adults under fasting conditions.
Johnson FK; Ciric S; Boudriau S; Kisicki JC; Stauffer J
Am J Ther; 2011 Jan; 18(1):2-8. PubMed ID: 20864883
[TBL] [Abstract][Full Text] [Related]
17. Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules.
Johnson FK; Ciric S; Boudriau S; Kisicki J; Stauffer J
J Clin Pharmacol; 2012 May; 52(5):747-56. PubMed ID: 21593282
[TBL] [Abstract][Full Text] [Related]
18. Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02).
Malhotra BK; Matschke K; Wang Q; Bramson C; Salageanu J
Clin Drug Investig; 2015 Apr; 35(4):267-74. PubMed ID: 25724154
[TBL] [Abstract][Full Text] [Related]
19. Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain.
Katz N; Hale M; Morris D; Stauffer J
Postgrad Med; 2010 Jul; 122(4):112-28. PubMed ID: 20675975
[TBL] [Abstract][Full Text] [Related]
20. Safety of EMBEda (morphine sulfate and naltrexone hydrochloride) extended-release capsules: review of postmarketing adverse events during the first year.
Badalamenti VC; Buckley JW; Smith ET
J Opioid Manag; 2012; 8(2):115-25. PubMed ID: 22616317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]